MicroVention vs. Balt USA: Neurovascular Coil Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | MicroVention, Inc. v. Balt USA, LLC |
| Case Number | 8:19-cv-01335 (C.D. Cal.) |
| Court | Central District of California |
| Duration | Jul 2019 – Apr 2024 4 years 9 months |
| Outcome | Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Balt Optima Coil System & XCEL Detachment Controller |
Case Overview
The Parties
⚖️ Plaintiff
California-based medical device company specializing in neurovascular products, including embolic coils. A subsidiary of Terumo Corporation.
🛡️ Defendant
U.S. arm of Balt Group, a French medical device manufacturer with neurovascular intervention products like the Optima Coil System and XCEL Detachment Controller.
Patents at Issue
This landmark case involved four U.S. patents covering neurovascular coil and detachment controller technology. These patents collectively protect the design, deployment, and detachment of embolic coils used in minimally invasive treatment of cerebral aneurysms.
- • US8182506B2 (App. No. US11/212830) — Covers embolic coil technology
- • US9717500B2 (App. No. US12/761113) — Relates to neurovascular coil systems
- • US20030154652A1 (App. No. US10/076338) — Early-generation coil application
- • US9414819B2 (App. No. US11/416826) — Coil delivery and detachment mechanisms
Designing a similar product?
Check if your neurovascular device design might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded via stipulated dismissal with prejudice under Federal Rule of Civil Procedure 41(a). All claims and counterclaims were terminated, and the court ordered that each party bear its own attorneys’ fees, costs, and expenses, except for obligations arising from prior court orders or separate agreements between the parties.
Key Legal Issues
The dismissal with prejudice following a joint stipulation signals a negotiated settlement agreement, likely involving undisclosed licensing terms or commercial arrangements. The mutual fee-bearing provision legally forecloses any future claim for “exceptional case” attorney fee shifting. This resolution type means no precedential claim construction or validity findings were generated, but it reinforces that multi-patent assertions against medical device competitors are frequently resolved through strategic settlement.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in neurovascular device design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in neurovascular IP
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Embolic coil systems & detachment technology
4 Patents Asserted
In neurovascular coil space
Complex IP Landscape
Requires deep analysis
✅ Key Takeaways
Stipulated dismissal with prejudice and mutual fee-bearing is consistent with confidential settlement; monitor related Balt and MicroVention patent activity for licensing signals.
Search related case law →Multi-patent assertions (4+ patents) significantly increase defense costs and settlement leverage in medical device litigation.
Explore precedents →Frequently Asked Questions
Four U.S. patents: US8182506B2, US9717500B2, US20030154652A1, and US9414819B2 — covering neurovascular embolic coil and detachment controller technology.
The parties filed a joint Stipulation of Dismissal (Doc. 371), and the court dismissed all claims and counterclaims with prejudice under FRCP 41(a), with each party bearing its own legal costs.
It reinforces multi-patent assertion as a leverage strategy and signals that well-resourced defendants can force negotiated resolution even in sustained infringement actions.
For patent holders, a portfolio-layering strategy with overlapping claim coverage is crucial. For accused infringers, early investment in IPR petitions can narrow the litigation. R&D teams must conduct comprehensive FTO analyses against active and continuation patents.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court, Central District of California — Case 8:19-cv-01335
- U.S. Patent and Trademark Office — Patent Full-Text Database
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41(a)
- Cornell Legal Information Institute — 35 U.S.C. § 285
- PatSnap — IP Intelligence Solutions for Medical Devices
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.